P
82.11
-0.97 (-1.17%)
| Penutupan Terdahulu | 83.08 |
| Buka | 82.45 |
| Jumlah Dagangan | 240,573 |
| Purata Dagangan (3B) | 900,532 |
| Modal Pasaran | 5,133,160,960 |
| Harga / Pendapatan (P/E TTM) | 124.41 |
| Harga / Pendapatan (P/E Ke hadapan) | 26.39 |
| Harga / Jualan (P/S) | 25.49 |
| Harga / Buku (P/B) | 8.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | 27.04% |
| Margin Operasi (TTM) | -68.18% |
| EPS Cair (TTM) | 0.780 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -88.90% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 381.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.65% |
| Nisbah Semasa (MRQ) | 17.25 |
| Aliran Tunai Operasi (OCF TTM) | 336.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 327.76 M |
| Pulangan Atas Aset (ROA TTM) | 2.48% |
| Pulangan Atas Ekuiti (ROE TTM) | 8.99% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Protagonist Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.7
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.70 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.10% |
| % Dimiliki oleh Institusi | 108.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Farallon Capital Management Llc | 30 Sep 2025 | 6,196,006 |
| Bvf Inc/Il | 30 Sep 2025 | 2,560,916 |
| Johnson & Johnson | 30 Sep 2025 | 2,449,183 |
| Janus Henderson Group Plc | 30 Sep 2025 | 1,100,821 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 115.00 (Citigroup, 40.06%) | Beli |
| Median | 102.00 (24.22%) | |
| Rendah | 81.00 (JP Morgan, -1.35%) | Beli |
| Purata | 97.71 (19.00%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 82.84 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 05 Jan 2026 | 110.00 (33.97%) | Beli | 84.18 |
| 28 Oct 2025 | 88.00 (7.17%) | Beli | 78.51 | |
| Barclays | 17 Dec 2025 | 108.00 (31.53%) | Beli | 89.34 |
| 07 Nov 2025 | 88.00 (7.17%) | Beli | 79.54 | |
| Citigroup | 08 Dec 2025 | 115.00 (40.06%) | Beli | 90.25 |
| 10 Nov 2025 | 98.00 (19.35%) | Beli | 83.23 | |
| Citizens | 07 Nov 2025 | 102.00 (24.22%) | Beli | 79.54 |
| JP Morgan | 07 Nov 2025 | 81.00 (-1.35%) | Beli | 79.54 |
| BTIG | 28 Oct 2025 | 82.00 (-0.13%) | Beli | 78.51 |
| Wedbush | 28 Oct 2025 | 86.00 (4.74%) | Beli | 78.51 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ALI ASIF | - | 83.42 | -8,588 | -716,411 |
| MOLINA ARTURO MD | - | 83.42 | -9,514 | -793,658 |
| PATEL DINESH V PH D | - | 83.42 | -34,438 | -2,872,818 |
| Jumlah Keseluruhan Kuantiti Bersih | -52,540 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -4,382,887 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 83.42 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ALI ASIF | Pegawai | 20 Jan 2026 | Jual (-) | 8,588 | 83.42 | 716,411 |
| PATEL DINESH V PH D | Pegawai | 20 Jan 2026 | Jual (-) | 34,438 | 83.42 | 2,872,818 |
| MOLINA ARTURO MD | Pegawai | 20 Jan 2026 | Jual (-) | 9,514 | 83.42 | 793,658 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Jan 2026 | Pengumuman | Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 |
| 05 Jan 2026 | Pengumuman | Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) |
| 06 Dec 2025 | Pengumuman | Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera |
| 27 Nov 2025 | Pengumuman | DELETED: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice |
| 06 Nov 2025 | Pengumuman | Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 03 Nov 2025 | Pengumuman | Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |